Literature DB >> 2529466

The repression of the growth factor-inducible genes JE, c-myc and stromelysin by adenovirus E1A is mediated by conserved region 1.

H van Dam1, R Offringa, A M Smits, J L Bos, N C Jones, A J van der Eb.   

Abstract

The growth factor-inducible cellular genes JE, c-myc and stromelysin (sml) are strongly repressed upon transformation by adenovirus E1A. As E1A proteins are multifunctional and apparently contain distinct domains (conserved regions 1, 2 and 3), each with a specific effect on gene regulation and cell-transformation, we have investigated which of the three conserved regions are responsible for the reduced expression of these genes. To this end, we monitored the expression of the JE, sml and c-myc genes in a panel of normal rat kidney (NRK) cells expressing different mutant E1A genes. Only CR1, and not CR2 or CR3 were found to be essential for the repression of the genes, indicating that CR1, one of the regions essential for cell transformation, represents an autonomous gene regulatory function that can operate in the absence of CR2. We also show that the association of E1A proteins to a 300 kD cellular protein in NRK cells coincides with the ability to repress these genes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2529466

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  A specific lysine in c-Jun is required for transcriptional repression by E1A and is acetylated by p300.

Authors:  R G Vries; M Prudenziati; C Zwartjes; M Verlaan; E Kalkhoven; A Zantema
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

2.  Scaffold/matrix attachment region elements interact with a p300-scaffold attachment factor A complex and are bound by acetylated nucleosomes.

Authors:  Joost H A Martens; Matty Verlaan; Eric Kalkhoven; Josephine C Dorsman; Alt Zantema
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  DNA-binding properties of the E1A-associated 300-kilodalton protein.

Authors:  Y Rikitake; E Moran
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

4.  The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines.

Authors:  M I Cockett; C R Bebbington; G T Yarranton
Journal:  Nucleic Acids Res       Date:  1991-01-25       Impact factor: 16.971

5.  Analysis with specific polyclonal antiserum indicates that the E1A-associated 300-kDa product is a stable nuclear phosphoprotein that undergoes cell cycle phase-specific modification.

Authors:  P Yaciuk; E Moran
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

6.  Maintenance of cellular proliferation by adenovirus early region 1A in fibroblasts conditionally immortalized by using simian virus 40 large T antigen requires conserved region 1.

Authors:  T E Riley; A Follin; N C Jones; P S Jat
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

7.  Positive and negative transcriptional elements of the human type IV collagenase gene.

Authors:  S M Frisch; J H Morisaki
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

8.  Differential effects of the adenovirus E1A oncogene on members of the AP-1 transcription factor family.

Authors:  H van Dam; R Offringa; I Meijer; B Stein; A M Smits; P Herrlich; J L Bos; A J van der Eb
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

9.  The N-terminal region of the adenovirus type 5 E1A proteins can repress expression of cellular genes via two distinct but overlapping domains.

Authors:  J C Dorsman; B M Hagmeyer; J Veenstra; P Elfferich; N Nabben; A Zantema; A J van der Eb
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Simian virus 40 large-T antigen expresses a biological activity complementary to the p300-associated transforming function of the adenovirus E1A gene products.

Authors:  P Yaciuk; M C Carter; J M Pipas; E Moran
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.